Table 1 Clinicopathologic characteristics of study population
| Â | Â | Total patients | CCRT | CCRT followed by adjuvant chemotherapy | P + value |
|---|---|---|---|---|---|
Case | Â | 120 | 30 | 90 | Â |
Median age, years (range) | 62.4 (24.2~87.0) | 63.4 (24.2~74.4) | 62.1 (38.8~87.0) | 0.87 | |
Men (%) | Â | 89 (74.2) | 20 (66.7) | 69 (76.7) | 0.25 |
Performance | ECOG 0-1 | 111 (92.5) | 28 (93.3) | 83 (92.2) | 0.73 |
| Â | ECOG 2 | 9 (7.5) | 2 (6.7) | 7 (7.8) | Â |
T stage (%) | T1 | 20 (16.7) | 4 (13.3) | 16 (17.8) | 0.53 |
| Â | T2 | 33 (27.5) | 6 (20.0) | 27 (30.0) | Â |
| Â | T3 | 51 (42.5) | 16 (53.3) | 35 (38.9) | Â |
| Â | T4 | 16 (13.3) | 4 (13.3) | 12 (13.3) | Â |
N stage (%) | N0 | 77 (64.2) | 18 (60.0) | 59 (65.6) | 0.58 |
| Â | N1 | 43 (35.8) | 12 (40.0) | 31 (34.4) | Â |
Stage (%) | IA | 13 (10.8) | 2 (6.7) | 11 (12.2) | 0.73 |
| Â | IB | 27 (22.5) | 5 (16.7) | 22 (24.4) | Â |
| Â | IIA | 29 (24.2) | 9 (30.0) | 20 (22.2) | Â |
| Â | IIB | 35 (29.2) | 10 (33.3) | 25 (27.8) | Â |
| Â | III | 16 (13.3) | 4 (13.3) | 12 (13.3) | Â |
RM status (%) | Negative | 79 (65.8) | 19 (63.3) | 60 (66.7) | 0.74 |
| Â | Positive | 41 (34.2) | 11 (36.7) | 30 (33.3) | Â |
CA 19-9 (%) | ≤ 60 U/ml | 57 (47.5) | 17 (56.7) | 40 (44.4) | 0.27 |
| Â | > 60 | 62 (51.7) | 13 (43.3) | 49 (54.4) | Â |
Tumor location (%) | Proximal | 59 (49.2) | 13 (43.3) | 46 (51.1) | 0.52 |
| Â | Distal | 55 (45.8) | 15 (50.0) | 40 (44.4) | Â |
Histologic grade (%) | WD/MD | 107 (89.2) | 29 (96.7) | 78 (86.7) | 0.29 |
| Â | PD | 11 (9.2) | 1 (3.3) | 10 (11.1) | Â |
Recurrence (%) | Local | 22 (32.4) | 5 (26.3) | 17 (34.7) | 0.51 |
| Â | Systemic | 46 (67.6) | 14 (73.7) | 32 (65.3) | Â |